(LEGN) Legend Biotech Corporation Business Model Canvas Research

Legend Biotech Corporation relies on CDMOs and GMP manufacturing partners to run tightly controlled cell-therapy steps, from viral-vector scale-up to cell processing and release testing. That support is critical for autologous products, where vein-to-vein timelines are often measured in days, not months, and any batch failure can delay treatment.

• Scales GMP capacity fast
• Supports release testing and QA
• Reduces supply-chain bottlenecks
• Protects time-sensitive autologous dosing

Academic researchers and scientific collaborators help Legend Biotech Corporation test new targets and indications early, before larger and costlier trials. Academic centers also generate first clinical evidence in solid tumors, lymphoma, and infectious disease, which can cut discovery risk and widen the innovation base.

• Early target validation
• First-in-human evidence
• Lower discovery risk
• Broader pipeline reach

Legend Biotech Corporation runs U.S., China, and ex-U.S. filings, inspections, and post-market duties for CARVYKTI, which was approved in the U.S. in 2022 and in China in 2023. Because CAR-T products face tight safety and CMC controls, compliance can delay or speed launch, and that directly shapes market access and revenue timing.

• U.S. and China approvals
• Inspection and CMC readiness
• Post-market safety tracking

Legend Biotech Corporation’s commercialization and medical affairs center on CARVYKTI, supported by its Janssen alliance, with 2024 global net sales of $963.5 million. The team drives physician education, product uptake, safety monitoring, and post-launch evidence generation so CARVYKTI can fit real-world treatment pathways.

• CARVYKTI drove $963.5 million in 2024 sales.
• Janssen handles much of the commercial reach.
• Medical affairs supports safety and evidence.

Legend Biotech Corporation’s GMP manufacturing know-how is a core moat because CAR-T production needs living-cell handling, chain-of-identity control, and batch release testing that are hard to copy. In 2024, Legend Biotech Corporation reported $1.0 billion+ in revenue, and this scale still depends on tight quality systems that protect every dose from vein to vein.

• Living cells are hard to standardize.
• Identity tracking prevents mix-ups.
• Release testing slows easy entry.

Legend Biotech relies on scientific talent in immunology, oncology, process development, and regulatory affairs to design trials, control release testing, and secure approvals. In advanced therapies, this human capital is a key moat: Legend Biotech’s 2024 revenue was $1.09 billion, and its CAR-T platform now depends on experts who can keep quality tight while scaling production.

• Trial design and endpoint strategy
• Batch release and CMC control
• FDA and global filing support
• Cross-functional therapy expertise

Legend Biotech Corporation’s autologous precision treatment uses each patient’s own cells, which helps drive high specificity and strong anti-tumor activity. CARVYKTI generated $1.59 billion in net product sales in 2024, showing how this customized approach has already scaled into a major commercial therapy.

• Own-cell manufacturing
• High tumor specificity
• Differentiated vs standard drugs

Legend Biotech Corporation runs development and commercialization work across the United States, China, and other international markets, which widens patient access and gives it more than one regulatory route. In fiscal 2024, the Company reported $1.08 billion in revenue, showing how that footprint already supports scale.

• U.S. and China hubs
• Broader patient reach
• Multiple approval paths
• Supports global launch scale

Janssen governance is one of Legend Biotech Corporation’s key enterprise ties: both teams jointly plan CARVYKTI development, share data, and execute commercialization, with decisions tied to milestone events and launch steps. CARVYKTI has already crossed $1 billion in annual sales, so this alliance directly affects a major revenue stream.

• Joint planning and decision-making
• Milestone-linked collaboration
• Data sharing and launch execution
• Core relationship for CARVYKTI growth

CAR-T care needs long follow-up for cytopenias, infections, CRS, and neurotoxicity, so Legend Biotech Corporation must keep tight pharmacovigilance and clinic support in place. That matters in 2025 because CARVYKTI continued to drive Legend Biotech Corporation’s commercial base, and safe use depends on fast AE reporting, trained centers, and clear monitoring pathways.

• Ongoing AE tracking supports safer CAR-T use
• Clinician support helps treatment-center readiness
• Trust boosts repeat adoption and access

Research hospitals and trial sites are a direct channel for Legend Biotech Corporation’s early-stage programs, because they recruit patients, give treatment, and collect endpoint data in one place. This matters most for pipeline work, where fast site activation can shape time to first patient in and overall study speed.

• Drives patient recruitment
• Supports drug administration
• Captures trial data

Legend Biotech Corporation relies on technical field teams to train physicians and hospital staff on CARVYKTI handling, patient eligibility, and safety steps, which matters because CAR-T use needs tight coordination across certified centers. In FY2024, Legend Biotech reported about $960 million in revenue, showing how critical medical education is to scaling adoption of a complex advanced therapy.

• Educates doctors and site staff
• Explains handling and eligibility
• Supports safe CAR-T adoption

Physicians and transplant specialists are the key gatekeepers for Legend Biotech Corporation’s CAR-T use: they confirm eligibility, choose treatment timing, and judge efficacy, safety, and sequencing versus transplant or other myeloma options. Their buy-in drives referral flow and hospital uptake, because CARVYKTI was used in relapsed/refractory multiple myeloma after prior lines in the U.S. and EU.

• Eligibility and sequencing drive access
• Safety review shapes adoption
• Clinical trust lifts referral volume

Insurers and integrated health systems gate access to CAR-T, because one treatment can exceed $400,000 and needs specialized infusion, inpatient monitoring, and site certification. For Legend Biotech Corporation, payer coverage directly shapes CARVYKTI use, with 2025 U.S. reimbursement and hospital adoption driving net revenue and market reach.

• Coverage decides patient access
• High cost slows adoption
• Health systems shape net sales

Sales, marketing, and medical affairs costs rise as CARVYKTI adoption expands, because Legend Biotech Corporation must fund field teams, payer support, and physician education. Under the Janssen collaboration, these launch costs are also shared and amplified by co-commercialization work across regions.

• Launch spend scales with adoption
• Includes field, access, and medical teams
• Janssen split adds commercial complexity

Legend Biotech Corporation carries permanent regulatory overhead from global filings, pharmacovigilance, and quality systems, and CAR-T products need long-term safety tracking, with FDA follow-up for some cell and gene therapies extending up to 15 years. In FY2025, this cost sat inside recurring R&D and SG&A spend, so it stays a fixed drag even after launch.

• Global filings never stop
• CAR-T needs long follow-up
• Quality systems are permanent

Compliance is not one-time spend; it scales with each market, label change, and post-market safety report.

Development milestones are a key revenue stream for Legend Biotech Corporation, with receipts tied to clinical, regulatory, and commercial wins in its CAR-T pipeline. These upfront cash inflows matter because they can fund new programs without immediate equity dilution, which is valuable for a deep pipeline and long development timelines.

• Cash arrives at defined pipeline milestones
• Supports R&D without new shares
• Best fit for multi-program biotechs

Legend Biotech Corporation’s future pipeline commercialization can add meaningful revenue if new CAR-T approvals in lymphoma, leukemia, gastric cancer, and other cancers reach market. In 2025, CARVYKTI remained the core cash engine, so any extra approved product would cut dependence on multiple myeloma; the upside still hinges on late-stage trial success and FDA/EMA approval.

• New approvals widen revenue mix
• Less reliance on CARVYKTI
• Clinical and regulatory risk stays high